#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lennox-Gastaut syndrome Lip and/or oral cavity cancer Postprandial hypoglycaemia SAPHO syndrome Hereditary angioedema with C1 esterase inhibitor deficiency Cutaneous T-cell lymphoma Congenital disorder of glycosylation Anal cancer recurrent Thrombotic microangiopathy Oesophageal adenocarcinoma stage II Gestational trophoblastic tumour Leukocyte adhesion deficiency B precursor type acute leukaemia Neonatal alloimmune thrombocytopenia Neuroblastoma recurrent More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Life with Disease Leiomyosarcoma – Treatment Alexander disease – Treatment Loeys-Dietz syndrome – Diagnostics Krabbe’s disease – Trials in Disease Angiosarcoma metastatic – Trials in Disease Acute respiratory distress syndrome – Basic Information Cerebral arteriovenous malformation haemorrhagic – Life with Disease Langerhans’ cell histiocytosis Glycogen storage disease type I – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Baxdrostat Ethambutol Asciminib Dexamfetamine Sulfate Mocravimod Sar441566 Xp-Dc+Tl+Klh 68Ga-Nota-Abscint-Her2 Resiquimod Sulfate Surzebiclimab Venlafaxine Empasiprubart Tipiracil Hydrochloride Dnth103 Kk8123 Chlorambucil Tecovirimat BMS-986365 FOSFOMYCIN CALCIUM Mirikizumab More therapies…

    Learn about Your Condition

    HER2 negative breast cancer Castleman's disease End stage renal disease Urethral valves Chondrocalcinosis Gestational diabetes Gastric cancer recurrent Cervix carcinoma stage I Albuminuria Colon cancer stage II Electrocorticogram Fungal infection Dengue fever Renal transplant Conjunctivitis allergic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. MVZ Onko Medical GmbH Hannover

MVZ Onko Medical GmbH Hannover

Pelikanplatz 23, List, Hanover, 30177, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Glatiramer Acetate
    • Topotecan
    Austria Belgium Czechia Denmark France Germany +6

  • Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Niraparib
    • Niraparib Tosilate Monohydrate
    • Bevacizumab
    Belgium Czechia Germany Italy

  • Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Pertuzumab
    • Atezolizumab
    Austria Belgium Germany Italy Romania Spain

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Camizestrant
    • Exemestane
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Infliximab
    • Mycophenolate Mofetil
    • Durvalumab
    Austria Belgium Bulgaria Denmark Finland France +6

  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Goserelin
    • Letrozole
    Austria Belgium France Germany Hungary Ireland +4

  • Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Doxorubicin
    • Paclitaxel
    • Pembrolizumab
    Belgium France Germany Hungary Ireland Poland +2

  • Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Cyclophosphamide Monohydrate
    • Atezolizumab
    Germany Spain

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!